Japan’s 1st Insulin Biosimilar Launched: Eli Lilly Japan, NBI

August 4, 2015

Eli Lilly Japan and Nippon Boehringer Ingelheim (NBI) launched on August 3 biosimilar versions of the basal insulin preparation Lantus (recombinant insulin glargine), Insulin Glargine BS Injection Cart “Lilly” and Insulin Glargine BS Injection MirioPen “Lilly”, the companies said on...read more